The ODD for was granted based on the results from the dose escalation part of the P-I/IIa (ReSPECT-LM) trial evaluating the MTD/MFD, safety & efficacy Rhenium (186Re) in patients with leptomeningeal metastases & post receiving FTD by the UD FDA
As per the results of Cohort 1-3 from the P-I portion of the trial, the CNS tumour cell count at day 28 in the 10 evaluable patients was reduced by ~53%. Additionally, Cohort 4 patient intake has been completed, and Cohort 5 enrollment is scheduled to start by EY 2023 following a standard safety evaluation
Trial updates are to be reported at SNO 2023. Additionally, the company is also evaluating Rhenium (186Re) in a P-I/II (ReSPECT-GBM trial) for recurrent glioma patients
Ref: Globenewswire | Image: Plus Therapeutics
Related News:- Plus Therapeutics Reports First Patient Dosing in P-I/IIa (ReSPECT-LM) Dose Escalation Trial of 186RNL for Leptomeningeal Metastases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
